With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway. Today, the FDA approved CSL’s garadacimab-gxii ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback